Rituximab is a chimeric anti CD-20 monoclonal antibody containing human IgG1 kappa constant regions, with murine variable regions. The anti-lymphoma effects of Rituximab are probably due to complement and antibody-dependent cell-mediated cytotoxicity, and induction of apoptosis. Phase II trials have demonstrated a strong activity of rituximab alone in indolent B non-Hodgkin lymphoma, especially in patients with follicular lymphoma. The most utilized dose-schedule is 375 mg/m2 weekly×4. The association with chemotherapy or with interferon-alpha increases Rituximab efficacy. More recently, Rituximab have showed activity also in diffuse large cell lymphoma, mantle cell lymphoma and in other B-malignancies. Good results have also been obtained utilizing Rituximab for in vivo purging. However, we are still far from having found a definite position for Rituximab in the treatment of lymphoproliferative disorders. The aim of future studies should be to develop new strategies that will hopefully produce the most effective Rituximab-based regimens in order to find the Rituximab key position in the treatment of B-malignancies

Treatment of B-cell low-grade non-Hodgkin's lymphoma with anti CD 20 monoclonal antibody Rituximab / Sacchi, Stefano; Federico, Massimo; G., Dastoli; C., Fiorani; G., Vinci; V., Clò; B., Casolari. - In: CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. - ISSN 1040-8428. - STAMPA. - 37(1):(2001), pp. 13-25. [10.1016/S1040-8428(00)00069-X]

Treatment of B-cell low-grade non-Hodgkin's lymphoma with anti CD 20 monoclonal antibody Rituximab.

SACCHI, Stefano;FEDERICO, Massimo;
2001

Abstract

Rituximab is a chimeric anti CD-20 monoclonal antibody containing human IgG1 kappa constant regions, with murine variable regions. The anti-lymphoma effects of Rituximab are probably due to complement and antibody-dependent cell-mediated cytotoxicity, and induction of apoptosis. Phase II trials have demonstrated a strong activity of rituximab alone in indolent B non-Hodgkin lymphoma, especially in patients with follicular lymphoma. The most utilized dose-schedule is 375 mg/m2 weekly×4. The association with chemotherapy or with interferon-alpha increases Rituximab efficacy. More recently, Rituximab have showed activity also in diffuse large cell lymphoma, mantle cell lymphoma and in other B-malignancies. Good results have also been obtained utilizing Rituximab for in vivo purging. However, we are still far from having found a definite position for Rituximab in the treatment of lymphoproliferative disorders. The aim of future studies should be to develop new strategies that will hopefully produce the most effective Rituximab-based regimens in order to find the Rituximab key position in the treatment of B-malignancies
2001
37(1)
13
25
Treatment of B-cell low-grade non-Hodgkin's lymphoma with anti CD 20 monoclonal antibody Rituximab / Sacchi, Stefano; Federico, Massimo; G., Dastoli; C., Fiorani; G., Vinci; V., Clò; B., Casolari. - In: CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. - ISSN 1040-8428. - STAMPA. - 37(1):(2001), pp. 13-25. [10.1016/S1040-8428(00)00069-X]
Sacchi, Stefano; Federico, Massimo; G., Dastoli; C., Fiorani; G., Vinci; V., Clò; B., Casolari
File in questo prodotto:
File Dimensione Formato  
Treatment of B-cell......pdf

Accesso riservato

Tipologia: Versione pubblicata dall'editore
Dimensione 231.82 kB
Formato Adobe PDF
231.82 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/309021
Citazioni
  • ???jsp.display-item.citation.pmc??? 9
  • Scopus 42
  • ???jsp.display-item.citation.isi??? 35
social impact